Deakin CT, Bowes J, Rider LG, Miller FW, Pachman LM, Sanner H, Rouster-Stevens K, Mamyrova G, Curiel R, Feldman BM, Huber AM, Reed AM, Schmeling H, Cook CG, Marshall LR, Ll Wilkinson MG, Eyre S, Raychaudhuri S, Wedderburn LR, Juvenile Dermatomyositis Cohort and Biomarker Study, the Childhood Myositis Heterogeneity Study Group, and the Myositis Genetics Consortium (MYOGEN) (2022)
Association with HLA-DRβ1 position 37 distinguishes juvenile dermatomyositis from adult-onset myositis
Hum Mol Genet, 31 (14), 2471-2481
DOI 10.1093/hmg/ddac019, PubMed 35094092

Giancane G, Papa R, Vastert S, Bagnasco F, Swart JF, Quartier P, Antón J, Kamphuis S, Sanner H, Glerup M, De Benedetti F, Tsitsami E, Remesal A, Moreno E, De Inocencio J, Myrup C, Pallotti C, Koné-Paut I, Franck-Larsson K, Malmström H, Cederholm S, Pistorio A, Wulffraat N, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) (2022)
Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry
J Rheumatol, 49 (4), 398-407
DOI 10.3899/jrheum.210563, PubMed 35105709

Mariette X, Barone F, Baldini C, Bootsma H, Clark KL, De Vita S, Gardner DH, Henderson RB, Herdman M, Lerang K, Mistry P, Punwaney R, Seror R, Stone J, van Daele P, van Maurik A, Wisniacki N, Roth DA, Tak PP (2022)
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome
JCI Insight, 7 (23)
DOI 10.1172/jci.insight.163030, PubMed 36477362